수모세포종 치료후 발생한 척추골절에서 파미드로네이트 치료 1례
Pamidronate Treatment in Vertebral Fracture after Off-therapy of Medulloblastoma
0
조회
0
다운로드
3
인용
0
참고문헌
초록
소아기에 발생한 수모세포종에서 골다공증의 발생률은 매우 높으며, 이는 대개 성장호르몬 결핍증이 그 주요 원인이다. 수모세포종 치료 후 정기적으로 성장호르몬 결핍 여부와 골다공증의 발생여부를 추적 관찰하는 것은 매우 중요하다. 골절이 동반되어 심한 통증을 호소하고 운동능력이 제한된 환자에서 파미드로네이트의 치료는 통증을 조절하고 골밀도를 증가시키며 삶의 질을 증진시킨다. 저자들은 척추골절을 보인 수모세포종 환자에서 파미드로네이트를 사용한 환자 1례를 문헌 고찰과 함께 보고하는 바이다.
Abstract
A twenty-one year old man, who had been treated for medulloblastoma 6 years ago, complained progressive right knee joints pain and back pain. Multiple thoracic vertebral compression fracture was detected in radiography. The bone mineral density(BMD) was in osteoporotic range in duel energy X- ray absorpometry. Growth hormone deficiency and primary hypothyroidism were detected after endocrine function test. We treated him by cyclic intravenous pamidronate because he had complained severe back pain and difficulty to walk. After pamidronate therapy, the pain was decreased and the BMD was increased. No severe adverse effect was noted. This is the first case report of pamidronate therapy in patient who had osteoporotic vertebral compression fracture due to a sequela of childhood medulloblastoma.
참고문헌 (18)
- McNeil D.E, "Incidence and trends in pediatric malignancies medulloblastoma", primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results., 2002, pp.39, 190~194
- Rood B.R, "Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges.", Semin Oncol, 31, pp.666~675 (2004)
- Gurney J.G, "Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study.", Cancer, 97, pp.663~673 (2003)
- Barr R.D, "Osteopenia in children surviving brain tumours.", Eur J Cancer, 34, pp.873~877 (1998)
- Krishnamoorthy P, "Osteopenia in children who have undergone posterior fossa or craniospinal irradiation for brain tumors.", Arch Pediatr Adolesc Med, 158, pp.491~496 (2004)
- Odame I, "Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood.", Pediatr Blood Cancer, 46, pp.357~362 (2006)
- Gilsanz V, "Osteoporosis after cranial irradiation for acute lymphoblastic leukemia.", J Pediatr, 117, pp.238~244 (1990)
- Clarson C.L, "Growth failure after treatment of pediatric brain tumors.", Pediatrics, 103, pp.37~42 (1999)
- 윤인석, "소아 수모세포종 환자에서 치료 후의 내분비적 장애와 성장변화", Korean Journal of Pediatrics, 49(3), pp.292~297 (2006), 대한소아과학회
- Mithal N.P, "Reduced bone mineral density in long-term survivors of medulloblastoma.", Br J Radiol, 66, pp.814~816 (1993)
- Amin S, "The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.", Arthritis Rheum, 42, pp.1740~1751 (1999)
- Homik J.E, "A meta-analysis on the use of bisphosphonates in corticosteroid induced osteoporosis.", J Rheumatol, 26, pp.1148~1157 (1999)
- Falcini F, "Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling.", Calcif Tissue Int, 58, pp.166~169 (1996)
- Geusens P, "Recovery from severe glucocorticoid-induced osteoporosis in an adolescent boy.", J Clin Densitom, 4, pp.389~394 (2001)
- Goldbloom E.B, "Osteoporosis at presentation of childhood ALL: management with pamidronate.", Pediatr Hematol Oncol, 22, pp.543~550 (2005)
- Glorieux F.H, "Cyclic administration of pamindronate in children with severe osteogenesis imperfecta.", N Engl J Med, 339, pp.947~952 (1998)
- Zacharin M, "Pamidronate treatment of osteogenesis imperfecta: lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.", J Pediatr Endocrinol Metab, 15, pp.163~174 (2002)
- Brumsen C, "Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis.", Medicine (Baltimore), 76, pp.266~283 (1997)